Dignitana AB Publishes Q1 2023 Interim Report
Revenue reaches record high with EBITDA positive Financial highlights Q1 2023 · Net sales amounted to 21.5 MSEK (15.9), an increase of 35 percent over the same period in 2022. · Operating result amounted to -3.5 MSEK (-6.1). · Net result after financial items amounted to -3.9 MSEK (-6.5). · Earnings per share were -0.06 SEK (-0.10). · Cash Balance amounted to 11.7 MSEK (11.3). · Average Daily Treatment Revenue (ADTR)* was 242 TSEK (179), an increase of 35 percent over the same period in 2022. · EBITDA positive for the period. Business highlights during the